Biohaven Ltd (BHVN)

$15.55 -0.50 (-3.12%)
Market Cap 2.42B
Revenue (ttm) 0.00
Net Income (ttm) -738.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 1.87
Volume 2,946,700
Avg Vol 3,061,710
Day's Range N/A - N/A
Shares Out 150.56M
Stochastic %K 56%
Beta 1.28
Analysts Strong Sell
Price Target $21.94

Company Profile

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinica...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 404 0410
Address:
215 Church Street, New Haven, United States
jsonm
jsonm Jul. 8 at 4:39 PM
$BHVN Let’s move
0 · Reply
Timefortendies77
Timefortendies77 Jul. 8 at 3:15 PM
$BHVN Days Matter.
0 · Reply
OnlyEverLong
OnlyEverLong Jul. 7 at 6:36 PM
$BHVN still kind of expecting to hear something about troriluzole reassessment before the July 17 options expire. Might be tough to hold onto the recent strength otherwise. Let's see if we can't get one of those $0.20-$0.50 runs into the close again for today though.
0 · Reply
Dheeraj_6
Dheeraj_6 Jul. 7 at 1:54 PM
$BHVN Why Why , stay strong please !
1 · Reply
sellthedip1
sellthedip1 Jul. 7 at 1:21 PM
$BHVN holding well.
0 · Reply
bio_stock
bio_stock Jul. 6 at 8:20 PM
$BHVN still no fda news… perhaps the fda is standing firm with bhvn?
2 · Reply
ChrisBAB
ChrisBAB Jul. 6 at 7:32 PM
Monday so far... $LXRX Back on track 📈 $NIXX Good week ahead. Very bullish. $URG Started new position. Very promising. $NEOV Started new position. Extremely bullish. $BHVN Above $18 soon? GLTA!!!
1 · Reply
Timefortendies77
Timefortendies77 Jul. 6 at 5:11 PM
$BHVN Biohaven has “spent considerable time advocating” for troriluzole in SCA in the past year, CEO Vlad Coric told BioSpace earlier this month. “We stand by the data and believe this is an approvable package, and we are continuing to interact with the FDA, and we will not stop advocating for patients that this should be approved.” Over the past month, several rare disease drug developers, including Disc Medicine and Replimune, have announced new alignment with the FDA regarding their own recently rejected drugs. Will Biohaven be next? https://www.biospace.com/fda/fdas-uniqure-regenxbio-reversals-could-bolster-other-near-term-rare-disease-applications
0 · Reply
STACKD0E
STACKD0E Jul. 4 at 1:35 AM
$BHVN $55 🙃✨️
1 · Reply
Timefortendies77
Timefortendies77 Jul. 2 at 9:27 PM
$BHVN Days Matter. Everyone have a good 4th. Ending the week in a good place.
0 · Reply
Latest News on BHVN
Biohaven announces completion of enrollment in RISE3 trial

2026-06-30T11:35:53.000Z - 8 days ago

Biohaven announces completion of enrollment in RISE3 trial

Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator

Jun 30, 2026, 7:30 AM EDT - 8 days ago

Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator

Biohaven falls -9.8%

2026-06-29T14:05:29.000Z - 9 days ago

Biohaven falls -9.8%

Biohaven enrolls first patient in Phase 3 trial of BHV-1300 for Graves’ disease

2026-06-29T11:35:56.000Z - 9 days ago

Biohaven enrolls first patient in Phase 3 trial of BHV-1300 for Graves’ disease

Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease

Jun 29, 2026, 7:30 AM EDT - 9 days ago

Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease

Biohaven downgraded to Underperform from Neutral at BofA

2026-06-29T10:20:18.000Z - 9 days ago

Biohaven downgraded to Underperform from Neutral at BofA

XENE

Biohaven rises 7.4%

2026-06-26T14:07:04.000Z - 12 days ago

Biohaven rises 7.4%

Biohaven price target raised to $20 from $15 at Deutsche Bank

2026-06-26T12:35:29.000Z - 12 days ago

Biohaven price target raised to $20 from $15 at Deutsche Bank

Biohaven initiates first-in-human dosing for BHV-8100

2026-06-01T11:42:14.000Z - 5 weeks ago

Biohaven initiates first-in-human dosing for BHV-8100

Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation

Jun 1, 2026, 7:30 AM EDT - 5 weeks ago

Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation

Biohaven’s candidates in Graves’ Disease and IgA nephropathy shows efficacy

2026-05-27T12:22:09.000Z - 6 weeks ago

Biohaven’s candidates in Graves’ Disease and IgA nephropathy shows efficacy

Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy

May 27, 2026, 7:30 AM EDT - 6 weeks ago

Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy

Biohaven reports data from selective Kv7.2/7.3 channel activator program

2026-05-26T12:55:10.000Z - 6 weeks ago

Biohaven reports data from selective Kv7.2/7.3 channel activator program

Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile

May 26, 2026, 7:30 AM EDT - 6 weeks ago

Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile

Biohaven price target lowered to $18 from $21 at Morgan Stanley

2026-05-13T16:59:45.000Z - 7 weeks ago

Biohaven price target lowered to $18 from $21 at Morgan Stanley

Biohaven price target lowered to $22 from $23 at RBC Capital

2026-05-05T12:31:27.000Z - 2 months ago

Biohaven price target lowered to $22 from $23 at RBC Capital

Biohaven price target lowered to $12 from $14 at BofA

2026-05-05T09:56:40.000Z - 2 months ago

Biohaven price target lowered to $12 from $14 at BofA

Biohaven files automatic mixed securities shelf

2026-05-04T20:38:11.000Z - 2 months ago

Biohaven files automatic mixed securities shelf

Biohaven reports Q1 adjusted EPS (69c), consensus (76c)

2026-05-04T20:15:04.000Z - 2 months ago

Biohaven reports Q1 adjusted EPS (69c), consensus (76c)

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

May 4, 2026, 4:02 PM EDT - 2 months ago

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

Biohaven Quarterly report: Q1 2026

May 4, 2026, 4:00 PM EDT - 2 months ago

Biohaven Quarterly report: Q1 2026

Biohaven Earnings release: Q1 2026

May 4, 2026, 4:00 PM EDT - 2 months ago

Biohaven Earnings release: Q1 2026

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Mar 19, 2026, 7:30 AM EDT - 3 months ago

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Biohaven Proxy statement: Proxy Filing

Mar 13, 2026, 8:00 AM EDT - 4 months ago

Biohaven Proxy statement: Proxy Filing

Biohaven Proxy statement: Proxy Filing

Mar 13, 2026, 8:00 AM EDT - 4 months ago

Biohaven Proxy statement: Proxy Filing

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

Mar 2, 2026, 4:05 PM EST - 4 months ago

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

Biohaven Annual report: Q4 2025

Mar 2, 2026, 4:00 PM EST - 4 months ago

Biohaven Annual report: Q4 2025

Biohaven Earnings release: Q4 2025

Mar 2, 2026, 4:00 PM EST - 4 months ago

Biohaven Earnings release: Q4 2025

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 11:15 AM EST - 6 months ago

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Biohaven Slides: 44th Annual J.P. Morgan Healthcare Conference presentation

Jan 12, 2026, 7:00 AM EST - 6 months ago

Biohaven Slides: 44th Annual J.P. Morgan Healthcare Conference presentation

Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

Jan 7, 2026, 7:00 AM EST - 6 months ago

Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

Biohaven's depression drug fails mid-stage trial, shares fall

Dec 24, 2025, 3:24 PM EST - 6 months ago

Biohaven's depression drug fails mid-stage trial, shares fall

Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder

Dec 24, 2025, 1:00 PM EST - 6 months ago

Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder

Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress

Dec 11, 2025, 7:00 AM EST - 7 months ago

Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress

Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M

Nov 13, 2025, 4:05 PM EST - 8 months ago

Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M

Biohaven Announces Pricing of $175 Million Public Offering of Common Shares

Nov 12, 2025, 7:15 AM EST - 8 months ago

Biohaven Announces Pricing of $175 Million Public Offering of Common Shares

Biohaven Announces Proposed Public Offering of Common Shares

Nov 11, 2025, 4:05 PM EST - 8 months ago

Biohaven Announces Proposed Public Offering of Common Shares

Biohaven Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 8 months ago

Biohaven Quarterly report: Q3 2025

Biohaven Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 8 months ago

Biohaven Earnings release: Q3 2025

Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments

Nov 10, 2025, 6:58 AM EST - 8 months ago

Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments

Biohaven shares plunge after US FDA declines to approve brain disorder drug

Nov 5, 2025, 10:02 AM EST - 8 months ago

Biohaven shares plunge after US FDA declines to approve brain disorder drug

FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia

Nov 4, 2025, 8:06 PM EST - 8 months ago

FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia

Biohaven Slides: Corporate Presentation

Aug 12, 2025, 8:00 PM EDT - 11 months ago

Biohaven Slides: Corporate Presentation

Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments

Biohaven Quarterly report: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Biohaven Quarterly report: Q2 2025

Biohaven Earnings release: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Biohaven Earnings release: Q2 2025

Law Offices of Frank R. Cruz Encourages Biohaven Ltd.

Jul 18, 2025, 12:06 PM EDT - 1 year ago

Law Offices of Frank R. Cruz Encourages Biohaven Ltd.

Law Offices of Howard G. Smith Encourages Biohaven Ltd.

Jul 18, 2025, 12:00 PM EDT - 1 year ago

Law Offices of Howard G. Smith Encourages Biohaven Ltd.

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biohaven Ltd. (BHVN)

Jul 15, 2025, 10:46 AM EDT - 1 year ago

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biohaven Ltd. (BHVN)

Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development

Jun 10, 2025, 2:00 PM EDT - 1 year ago

Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development

jsonm
jsonm Jul. 8 at 4:39 PM
$BHVN Let’s move
0 · Reply
Timefortendies77
Timefortendies77 Jul. 8 at 3:15 PM
$BHVN Days Matter.
0 · Reply
OnlyEverLong
OnlyEverLong Jul. 7 at 6:36 PM
$BHVN still kind of expecting to hear something about troriluzole reassessment before the July 17 options expire. Might be tough to hold onto the recent strength otherwise. Let's see if we can't get one of those $0.20-$0.50 runs into the close again for today though.
0 · Reply
Dheeraj_6
Dheeraj_6 Jul. 7 at 1:54 PM
$BHVN Why Why , stay strong please !
1 · Reply
sellthedip1
sellthedip1 Jul. 7 at 1:21 PM
$BHVN holding well.
0 · Reply
bio_stock
bio_stock Jul. 6 at 8:20 PM
$BHVN still no fda news… perhaps the fda is standing firm with bhvn?
2 · Reply
ChrisBAB
ChrisBAB Jul. 6 at 7:32 PM
Monday so far... $LXRX Back on track 📈 $NIXX Good week ahead. Very bullish. $URG Started new position. Very promising. $NEOV Started new position. Extremely bullish. $BHVN Above $18 soon? GLTA!!!
1 · Reply
Timefortendies77
Timefortendies77 Jul. 6 at 5:11 PM
$BHVN Biohaven has “spent considerable time advocating” for troriluzole in SCA in the past year, CEO Vlad Coric told BioSpace earlier this month. “We stand by the data and believe this is an approvable package, and we are continuing to interact with the FDA, and we will not stop advocating for patients that this should be approved.” Over the past month, several rare disease drug developers, including Disc Medicine and Replimune, have announced new alignment with the FDA regarding their own recently rejected drugs. Will Biohaven be next? https://www.biospace.com/fda/fdas-uniqure-regenxbio-reversals-could-bolster-other-near-term-rare-disease-applications
0 · Reply
STACKD0E
STACKD0E Jul. 4 at 1:35 AM
$BHVN $55 🙃✨️
1 · Reply
Timefortendies77
Timefortendies77 Jul. 2 at 9:27 PM
$BHVN Days Matter. Everyone have a good 4th. Ending the week in a good place.
0 · Reply
ChrisBAB
ChrisBAB Jul. 2 at 4:24 PM
$BHVN
0 · Reply
OnlyEverLong
OnlyEverLong Jul. 2 at 2:26 PM
$BHVN continuing to show strength even without news surrounding a potential troriluzole reassessment yet. The put/call ratio says it all though.
1 · Reply
BapoRothstein
BapoRothstein Jul. 1 at 10:23 PM
$BHVN is the haven for biotech investors. That’s why it’s called Biohaven. Soon to be Forty-Dollar-Biohaven.
1 · Reply
Timefortendies77
Timefortendies77 Jul. 1 at 8:56 PM
$BHVN this just in "Biohaven runs hard into close to nearly $16 a share, almost making back the full drop from the biased BofA article and coordinated short attack that launched n Monday 9/29. Traders are expecting SCA, Epilepy, and Obesity updates in the coming months." @OnlyEverLong
0 · Reply
OnlyEverLong
OnlyEverLong Jul. 1 at 7:55 PM
$BHVN When is the stocktwits "Why is BHVN stock rising into the close?" article coming out?
1 · Reply
BapoRothstein
BapoRothstein Jul. 1 at 7:34 PM
$BHVN
0 · Reply
jsonm
jsonm Jul. 1 at 6:15 PM
$BHVN
0 · Reply
Timefortendies77
Timefortendies77 Jul. 1 at 5:51 PM
$BHVN You know you want 16 back, let's go there!
0 · Reply
Ccg_
Ccg_ Jul. 1 at 5:51 PM
$BHVN keeps trying to breakout
0 · Reply
Dirtdemon75
Dirtdemon75 Jul. 1 at 5:18 PM
$BHVN
0 · Reply
Timefortendies77
Timefortendies77 Jun. 30 at 9:03 PM
$BHVN The afterhours and premarket games are comical, institutions are holding the line during market hours. If SCA T drug gets reassessed things will change very quickly.
0 · Reply
black_fox
black_fox Jun. 30 at 8:06 PM
$BHVN 3 big catalysts for the rest of the year: sca, epilepsy and obesity
1 · Reply